RhumbLine Advisers
DNA icon

RhumbLine Advisers’s Ginkgo Bioworks DNA Stock Holding History

RhumbLine Advisers’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$308K Buy
50,283
+1,412
+3% +$11.7K ﹤0.01% 2905
2025
Q4 		$406K Sell
48,871
-9,110
-16% -$98.1K ﹤0.01% 2793
2025
Q3 		$845K Sell
57,981
-1,249
-2% -$14.9K ﹤0.01% 2346
2025
Q2 		$666K Buy
+59,230
New +$459K ﹤0.01% 2484
2024
Q3 		– Sell
-3,516
Closed -$47K – 4236
2024
Q2 		$47K Sell
3,516
-33,299
-90% -$994K ﹤0.01% 3702
2024
Q1 		$1.71M Sell
36,815
-5,041
-12% -$261K ﹤0.01% 1977
2023
Q4 		$2.83M Buy
41,856
+1,298
+3% +$79.5K ﹤0.01% 1729
2023
Q3 		$2.94M Sell
40,558
-84
-0.2% -$6.72K ﹤0.01% 1654
2023
Q2 		$3.02M Buy
40,642
+18,023
+80% +$1.07M ﹤0.01% 1680
2023
Q1 		$1.2M Buy
22,619
+1,425
+7% +$90.3K ﹤0.01% 2042
2022
Q4 		$1.43M Buy
21,194
+2,618
+14% +$241K ﹤0.01% 1957
2022
Q3 		$2.32M Buy
18,576
+36
+0.2% +$4.29K ﹤0.01% 1670
2022
Q2 		$1.76M Buy
18,540
+17,410
+1,541% +$2.12M ﹤0.01% 1829
2022
Q1 		$182K Hold
1,130
– – ﹤0.01% 2781
2021
Q4 		$376K Buy
+1,130
New +$537K ﹤0.01% 2624

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's DNA Position: Q1 2026 in Review

RhumbLine Advisers increased its Ginkgo Bioworks (DNA) stake by 2.9% in Q1 2026, buying an estimated $11.7K and bringing the position to 50,283 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2905.

RhumbLine Advisers first reported a position in DNA in Q4 2021 and has held it in 15 quarters since. The position peaked at $3.02M in Q2 2023. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • RhumbLine Advisers held 50,283 shares of Ginkgo Bioworks worth $308K as of Q1 2026.
  • RhumbLine Advisers bought 1,412 Ginkgo Bioworks shares in Q1 2026, an estimated $11.7K.
  • Ginkgo Bioworks made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2905 holding.
  • RhumbLine Advisers first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 15 quarters since.
  • RhumbLine Advisers's Ginkgo Bioworks position peaked at $3.02M in Q2 2023.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.